Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Clinical trial NCT04007835 · UNKNOWN
Trial details
- NCT number
- NCT04007835
- Sponsor
- Guangdong Association of Clinical Trials
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-01
- Primary completion
- 2021-07-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.